Operator Good morning. My name is Vaishnavi, and I'll be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' Fourth Quarter and Full Year 2020 Financial Results Conference Call. There will be a question-and-answer session to follow. [Operator Instructions] I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Senior Vice President, Investor and Public Relations. Please go ahead. Ian Karp -- Senior Vice President, Investor And Public Relations Thanks so much. And thank you all for joining us on today's conference call to discuss Karyopharm's fourth quarter and full year 2020 financial results and business update. This is Ian Karp. And I'm joined today by Dr. Michael Kauffman, our Chief Executive Officer; Mr. Mike Mason, Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; Dr. Jatin Shah, Chief Medical Officer; and Mr. Stephen Mitchener, Chief Business Officer. On the call today, Michael will provide an overview of key recent corporate developments and an update on our commercial progress. And then Mike Mason will provide an overview of the fourth quarter and full year 2020 financial results.